Skip to main content

Table 1 Current non-pharmaceutical disease-modifying ongoing clinical trials

From: Novel targeted therapies for Parkinson’s disease

Mechanism

Intervention

ClinTrial Indentifier

Phase

Τarget population

Primary outcome

Other secondary outcomes of interest

Sponsor

Gene therapies

Vector genome: VY-AADC02

NCT03562494

II

Moderate to Advanced PD with motor Fluctuations

Changes in ON time without troublesome dyskinesia

.

Neurocrine Biosciences

 

Lentiviral vector:

OXB-102

NCT03720418

I/II

Bilateral PD

AE, SAE, Changes in MRI

.

Sio Gene Therapies

Neuromodulation

MRgFUS

NCT04002596

NCT03319485

NCT02263885

NCT02246374

NCT03608553

NA

Advanced PD

AE,

Responders,

Changes in CRST,

Changes in MDS-UPDRS

.

InSightec

Neuromodulation

rTMS

NCT04238000

NA

PD

Motor Outcomes

.

Fondazione Europea di Ricerca Biomedica Ferb Onlus

  

NCT04431570

NA

PD, freezing of gait

Changes in FOGT

fMRI

Peking Union Medical College Hospital

  

NCT04116216

II

PD

Changes in MDS-UPDRS part III

.

Universidade Federal de Pernambuco

  

NCT03836950

I/II

PD

Changes in Cognitive Outcomes

.

VA Office of Research and Development

  

NCT02346708

NA

PD with MCI

Changes in magnetoencephalography connectivity measures

.

University of Colorado, Denver

  

NCT03552861

NA

PD with Depression or Cognitive Impairment

Changes in HAMD and BDI

.

Guangdong Provincial People’s Hospital

  1. AE Adverse Events, BDI Beck Depression Inventory, CRST Clinical Rating Scale for Tremor, fMRI functional Magnetic Resonance Imaging, FOGT Freezing Of Gait Questionnaire, HAMD Hamilton Depression Scale, MCI Mild Cognitive Impairment, MDS-UPDRS MDS-Unified Parkinson’s Disease Rating Scale, MRgFUS Magnetic Resonance Guided Focused Ultrasound, MRI Magnetic Resonance Imaging, NA Not Applicable; rTMS Repetitive Transcranial Magnetic Stimulation, PD Parkinson’s Disease